Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Updated on 10 May 2022
organ transplantation
bronchiolitis obliterans
lung transplant


The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).



Condition Bronchiolitis Obliterans Syndrome BOS Bronchiolitis Obliterans Syndrome (BOS), Organ Transplant, Inflammation
Clinical Study IdentifierTX233326
Last Modified on10 May 2022


Yes No Not Sure

Inclusion Criteria

Double lung transplantation ≥ 1 year before informed consent
Confirmed BOS progression to Grade 1, 2, or 3 diagnosed within 1 year of screening OR Confirmed BOS Grade 1, 2, or 3 diagnosed within 2 years of screening AND 1) A ≥ 200 mL decrease in FEV1 in the previous 12 months OR 2) A ≥ 50 mL decrease in FEV1 in the last 2 measurements
Willingness to avoid pregnancy or fathering children

Exclusion Criteria

History of a single lung transplant
FEV1 decline attributable to cause(s) other than BOS
Participants who have had any significant change (eg, addition of new agents) in an immunosuppressive regimen in the 4 weeks before screening
Untreated and/or symptomatic gastroesophageal reflux disease
Significant infectious comorbidities including invasive fungal disease, B. Cepacia, non TB mycobacteria, or TB
Receipt of JAK inhibitor therapy after lung transplant for any indication. Treatment with a JAK inhibitor before lung transplant is permitted
Laboratory values at screening outside the protocol-defined ranges
Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (ie, positive HBsAg)
Known HIV infection
History of active malignancy within 3 years of screening
Women who are pregnant or breastfeeding
Treatment with an investigational agent, procedure, or device within 30 days of enrollment, or within 5 half-lives of the investigational product, whichever is longer
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note